VANI Stock Overview
A preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Vivani Medical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.16 |
| 52 Week High | US$7.80 |
| 52 Week Low | US$1.00 |
| Beta | 3.44 |
| 1 Month Change | -13.43% |
| 3 Month Change | -1.69% |
| 1 Year Change | 2.65% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -71.98% |
Recent News & Updates
Recent updates
We Think Vivani Medical (NASDAQ:VANI) Needs To Drive Business Growth Carefully
Aug 19
Is Vivani Medical (NASDAQ:VANI) In A Good Position To Invest In Growth?
Dec 23Here's Why We're Watching Vivani Medical's (NASDAQ:VANI) Cash Burn Situation
Jul 13Companies Like Vivani Medical (NASDAQ:VANI) Are In A Position To Invest In Growth
Apr 07We Think Vivani Medical (NASDAQ:VANI) Can Afford To Drive Business Growth
Dec 06Shareholder Returns
| VANI | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -10.8% | -0.3% | -0.4% |
| 1Y | 2.7% | 10.5% | 24.8% |
Return vs Industry: VANI underperformed the US Medical Equipment industry which returned 10.1% over the past year.
Return vs Market: VANI underperformed the US Market which returned 23.9% over the past year.
Price Volatility
| VANI volatility | |
|---|---|
| VANI Average Weekly Movement | 7.0% |
| Medical Equipment Industry Average Movement | 7.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: VANI has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: VANI's weekly volatility has decreased from 39% to 7% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 36 | Adam Mendelsohn | www.vivani.com |
Vivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature, subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant is under development for metabolic diseases in cats including for the treatment of obesity and diabetes.
Vivani Medical, Inc. Fundamentals Summary
| VANI fundamental statistics | |
|---|---|
| Market cap | US$68.71m |
| Earnings (TTM) | -US$23.46m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.9x
P/E RatioIs VANI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VANI income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$23.46m |
| Earnings | -US$23.46m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.40 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did VANI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 04:11 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Vivani Medical, Inc. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yi Chen | H.C. Wainwright & Co. |
| Nazibur Rahman | Maxim Group |
| Ashok Kumar | ThinkEquity LLC |